Rapt Therapeutics Inc
NASDAQ:RAPT
Operating Margin
Rapt Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Rapt Therapeutics Inc
NASDAQ:RAPT
|
297m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
390.5B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
140.9B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
99B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
96B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.4B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
58.9B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Rapt Therapeutics Inc
Glance View
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. FLX475 is in Phase I/II clinical trials. Its lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Rapt Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet